To examine associations between MC4R gene variants and weight changes following a switch to integrase inhibitor-containing antiretroviral therapy in persons with HIV, highlighting the potential implications for treatment strategies.
Key Findings:
Three MC4R variants were significantly associated with weight change post-switch (P < .05), suggesting a genetic basis for weight gain.
62% of participants were overweight or obese at the time of switch, indicating a need for targeted interventions.
Findings suggest a neuroendocrine contribution to weight gain associated with integrase inhibitors, which could inform future treatment strategies.
Interpretation:
The study supports the hypothesis that genetic factors, particularly MC4R variants, influence weight changes in persons with HIV transitioning to integrase inhibitor therapy, potentially guiding personalized treatment approaches.
Limitations:
Exploratory nature of the study; findings require validation in larger cohorts to confirm associations.
Potential confounding factors, such as lifestyle and metabolic health, were not fully accounted for in the analysis, which may affect the results.
Conclusion:
MC4R gene variants may play a role in weight gain following the switch to integrase inhibitor-based ART, indicating a need for personalized treatment approaches that consider genetic factors.
by Todd Hulgan, Kristine M Erlandson, Yuki Bradford, Katherine Tassiopoulos, Kunling Wu, Sara H Bares, Todd T Brown, Jordan E Lake, Michael Leonard, Grace A McComsey, Marylyn D Ritchie, Paul E Sax, John R Koethe, David W Haas
